guidelines

This JAMA Clinical Guidelines Synopsis summarizes the American College of Cardiology and American Heart Association’s 2024 guidelines on management of lower extremity peripheral artery disease.

Author/s:

Aman Kansal, MD, Andrew M. Davis, MD, MPH, Jennifer A. Rymer, MD, MBA

Management of Peripheral Artery Disease

Megan George — Sun, 06 Jul 2025 18:44:50 +0000

Date Added:

July 6, 2025

Journal/Publication:

JAMA Clinical Guidelines Synopsis

Publication Date:

July 2, 2025

URL:

https://jamanetwork.com/journals/jama/fullarticle/2835911?guestAccessKey=4bf0464…

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

doi:10.1001/jama.2025.8408

Keywords

guidelines

surgery

vascular surgery

peripheral arterial disease

Cardiology

PMID (1):

40601325

MeSH

Peripheral Vascular Diseases

atherosclerosis

Ischemia

Guidance regarding management of patients with peripheral artery disease. James W. Mold, MD, MPH

View

This JAMA Clinical Guidelines Synopsis summarizes the American College of Cardiology and American Heart Association’s 2024 guidelines on management of lower extremity peripheral artery disease.

Author/s:

Aman Kansal, MD, Andrew M. Davis, MD, MPH, Jennifer A. Rymer, MD, MBA

Topical Therapies for Atopic Dermatitis

Rowan Hutchins — Sun, 12 Nov 2023 21:20:37 +0000

Date Added:

November 12, 2023

Journal/Publication:

JAMA

Publisher:

AMA

Publication Date:

October 27, 2023

URL:

Topical Therapies for Atopic Dermatitis

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.1001/jama.2023.17719

Keywords

Atopic Dermatitis

guidelines

allergy and clinical immunology

PMID (1):

37889498

MeSH

Dermatitis, Atopic

dermatology

Practice Guidelines as Topic / standards*

clinical decision-making

A summary of current topical treatment options for atopic dermatitis. James W. Mold, MD, MPH

Commercial full text (fees may apply)

View

Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting approximately 10% of the US population. AD often occurs as a childhood disease in conjunction with allergies and asthma, but it can also persist into or arise de novo in adulthood. AD negatively affects quality of life, social interactions, and work productivity, with annual US health care costs exceeding $5.3 billion.1 The current guideline provides recommendations on the management of AD in adults with both nonpharmacologic and pharmacologic topical therapies

Author/s:

Amy Z. Xu, Jason T. Alexander

2020 Focused Updates to the Asthma Management Guidelines: At-a-Glance Guide

Aubrey Delammermore — Wed, 12 Apr 2023 05:00:00 +0000

Date Added:

April 12, 2023

Journal/Publication:

NIH Publication No. 20-HL-8142

Publisher:

US Department of Health and Human Services

Publication Date:

December 1, 2020

URL:

2020 Focused Updates to the Asthma Management Guidelines: At-a-Glance Guide

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

Keywords

MeSH

Patient Care Management

asthma

Judgment

Anti-Asthmatic Agents

A concise summary of the 2020 NIH Guidelines for management of asthma. James W. Mold, MD, MPH

Free full text

View

This At-A-Glance Guide describes a treatment management approach based on recommendations from the 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Step diagrams from the 2007 Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3) were updated with the new recommendations. The diagrams are intended to help clinicians integrate the new recommendations into clinical care, and are meant to assist, and not replace, clinical judgment or decision-making for individual patient
management, with input from individuals with asthma about their preferences

Personal and Social Activities

Brian Desmarais — Thu, 19 Nov 2020 16:36:36 +0000

Date Added:

November 19, 2020

Publisher:

CDC

Publication Date:

October 29, 2020

URL:

Personal and Social Activities

Type:

Patient Education Materials

Format:

Web Page

Keywords

guidelines

social guidelines

MeSH

Social Control, Formal

Centers for Disease Control and Prevention, U.S.

Advice from the CDC on precautions to take when planning social gatherings during the pandemic. James W. Mold, MD, MPH

Free full text

View

Not available.

Coronavirus Disease 2019 (COVID-19) Treatment Guidelines

John Bayhi — Thu, 23 Apr 2020 16:41:46 +0000

Date Added:

April 25, 2020

Journal/Publication:

NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines Website

Publisher:

U.S. Department of Health & Human Services / National Institutes of Health

Publication Date:

April 21, 2020

URL:

Coronavirus Disease 2019 (COVID-19) Treatment Guidelines

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Web Page

Keywords

COVID-19

treatment

guidelines

2019 novel coronavirus

2019-nCOV

NIH COVID-19 treatment guidelines as of April 23, 2020. James W. Mold, MD, MPH

Free full text

View

No abstract available.

Author/s:

COVID-19 Treatment Guidelines Panel

Guidance for Retirement Communities and Independent Living

Brian Desmarais — Tue, 24 Mar 2020 16:18:13 +0000

Date Added:

March 24, 2020

Publication Date:

March 20, 2020

URL:

Guidance for Retirement Communities and Independent Living

Type:

Public Health Announcements

Format:

Web Page

Keywords

guidelines

retirement communities

independent living centers

2019 novel coronavirus

MeSH

COVID-19

cough

severe acute respiratory syndrome coronavirus 2

CDC COVID19 advice for retirement communities and independent living centers for the elderly and disabled. James W. Mold, MD, MPH

Free full text

View

Not available.

Author/s:

Centers for Disease Control and Prevention (CDC)

Canadian practice guidelines for the treatment of children and adolescents with eating disorders

Brian Desmarais — Tue, 10 Mar 2020 16:04:09 +0000

Date Added:

March 10, 2020

Journal/Publication:

Journal of Eating Disorders

Publication Date:

February 8, 2020

Volume:

URL:

Canadian practice guidelines for the treatment of children and adolescents with eating disorders

Type:

Practice Management Reviews and Guidelines

Format:

Article

DOI (1):

10.1186/s40337-020-0277-8

Keywords

Anorexia nervosa

Avoidant/restrictive food intake disorder

Bulimia nervosa

guidelines

MeSH

Feeding and Eating Disorders

This is a 2020 evidence-based guideline from Canada on management of eating disorders in children and adolescents. It is long and comprehensive. (Potentially useful as a reference when you have a child with an apparent eating disorder.) James W. Mold, MD, MPH

Free full text

View

Abstract
Objectives: Eating disorders are common and serious conditions affecting up to 4% of the population. The
mortality rate is high. Despite the seriousness and prevalence of eating disorders in children and adolescents, no
Canadian practice guidelines exist to facilitate treatment decisions. This leaves clinicians without any guidance as to
which treatment they should use. Our objective was to produce such a guideline.
Methods: Using systematic review, the Grading of Recommendations Assessment, Development, and Evaluation
(GRADE) system, and the assembly of a panel of diverse stakeholders from across the country, we developed high
quality treatment guidelines that are focused on interventions for children and adolescents with eating disorders.
Results: Strong recommendations were supported specifically in favour of Family-Based Treatment, and more
generally in terms of least intensive treatment environment. Weak recommendations in favour of Multi-Family
Therapy, Cognitive Behavioural Therapy, Adolescent Focused Psychotherapy, adjunctive Yoga and atypical
antipsychotics were confirmed.
Conclusions: Several gaps for future work were identified including enhanced research efforts on new primary and
adjunctive treatments in order to address severe eating disorders and complex co-morbidities.
Keywords: Guidelines, Adolescent, Anorexia nervosa, Bulimia nervosa, Avoidant/restrictive food intake disorder

Author/s:

Couturier, J., Isserlin, L., Norris, M., Spettigue, W., Brouwers, M., Kimber, M., McVey, G., Webb, C., Findlay, S., Bhatnagar, N., Snelgrove, N., Ritsma, A., Preskow, W.

Recommended Adult Immunization Schedule, United States, 2020

Brian Desmarais — Tue, 04 Feb 2020 15:28:01 +0000

Date Added:

February 4, 2020

Journal/Publication:

Annals of Internal Medicine

Publication Date:

February 4, 2020

Volume:

Online

URL:

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.7326/M20-0046

Keywords

guidelines

adult immunization

MeSH

Immunization Schedule

Centers for Disease Control and Prevention

Centers for Medicare and Medicaid Services (U.S.)

Adults

2020 guidelines for adult immunizations with printable charts. James W. Mold, MD, MPH

Free full text

View

In October 2019, the Advisory Committee on Immunization Practices (ACIP) voted to approve the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2020. The 2020 adult immunization schedule, available at www.cdc.gov/vaccines/schedules/hcp/imz/adult.html, summarizes ACIP recommendations in 2 tables and accompanying notes (Figure). The full ACIP recommendations for each vaccine are available at www.cdc.gov/vaccines/hcp/acip-recs/index.html. The 2020 schedule has also been approved by the director of the Centers for Disease Control and Prevention (CDC) and by the American College of Physicians (www.acponline.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), and American College of Nurse-Midwives (www.midwife.org).

Author/s:

Freedman, M., Kroger, A., Hunter, P., Ault, K.A.

Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians

John Bayhi — Tue, 07 Jan 2020 19:22:41 +0000

Date Added:

January 7, 2020

Journal/Publication:

Annals of Internal Medicine

Publisher:

American College of Physicians

Publication Date:

January 7, 2020

URL:

Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.7326/M19-0882

Keywords

testosterone

guidelines

age-related testosterone deficiency

PMID (1):

31905405

MeSH

depressive disorder, major

Sexual Dysfunction

Physiological

Cognition

cardiovascular diseases

It appears that testosterone replacement in men with documented age-related testosterone deficiency may have small benefits in terms of sexual function and quality of life with no effect on physical function and no increase in significant adverse events. James W. Mold, MD, MPH

Free full text

View

DESCRIPTION:

The American College of Physicians (ACP) developed this guideline to provide clinical recommendations based on the current evidence of the benefits and harms of testosterone treatment in adult men with age-related low testosterone. This guideline is endorsed by the American Academy of Family Physicians.

METHODS:

The ACP Clinical Guidelines Committee based these recommendations on a systematic review on the efficacy and safety of testosterone treatment in adult men with age-related low testosterone. Clinical outcomes were evaluated by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system and included sexual function, physical function, quality of life, energy and vitality, depression, cognition, serious adverse events, major adverse cardiovascular events, and other adverse events.

TARGET AUDIENCE AND PATIENT POPULATION:

The target audience includes all clinicians, and the target patient population includes adult men with age-related low testosterone.

RECOMMENDATION 1A:

ACP suggests that clinicians discuss whether to initiate testosterone treatment in men with age-related low testosterone with sexual dysfunction who want to improve sexual function (conditional recommendation; low-certainty evidence). The discussion should include the potential benefits, harms, costs, and patient's preferences.

RECOMMENDATION 1B:

ACP suggests that clinicians should reevaluate symptoms within 12 months and periodically thereafter. Clinicians should discontinue testosterone treatment in men with age-related low testosterone with sexual dysfunction in whom there is no improvement in sexual function (conditional recommendation; low-certainty evidence).

RECOMMENDATION 1C:

ACP suggests that clinicians consider intramuscular rather than transdermal formulations when initiating testosterone treatment to improve sexual function in men with age-related low testosterone, as costs are considerably lower for the intramuscular formulation and clinical effectiveness and harms are similar.

RECOMMENDATION 2:

ACP suggests that clinicians not initiate testosterone treatment in men with age-related low testosterone to improve energy, vitality, physical function, or cognition (conditional recommendation; low-certainty evidence).

Author/s:

Qaseem, A., Horwitch, CA, Vijan, S, Etxeandia-Ikobaltzeta, I, Kansagara, D, Clinical Guidelines Committee of the American College of Physicians

Primary Prevention of Cardiovascular Disease

John Bayhi — Sat, 05 Oct 2019 14:48:41 +0000

Date Added:

October 5, 2019

Journal/Publication:

JAMA

Publisher:

American Medical Association

Publication Date:

October 4, 2019

URL:

Primary Prevention of Cardiovascular Disease

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.1001/jama.2019.15915

Keywords

CAD

coronary artery disease

guidelines

American Heart Association

American College of Cardiology

CVD

cardiovascular disease

primary prevention

PMID (1):

31584604

The most recent ACC/AHA Guideline regarding primary prevention of coronary artery disease. James W. Mold, MD, MPH

Commercial full text (fees may apply)

View

Atherosclerotic CVD remains the leading cause of death for people of most racial/ethnic groups. In 2010, the AHA suggested metrics of ideal cardiovascular health in 7 domains (blood pressure, physical activity, cholesterol, diet, weight, smoking, and blood glucose). There have since been multiple related guideline updates and scientific statements. In 2017, the ACC/AHA Task Force on Clinical Practice Guidelines commissioned an updated guideline integrating existing and new recommendations into a unified and “user-friendly” document on primary prevention of ASCVD.

Author/s:

Jain, A, Davis, AM

Assessment and Management of Patients at Risk for Suicide: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines.

Brian Desmarais — Wed, 28 Aug 2019 19:36:58 +0000

Date Added:

August 28, 2019

Journal/Publication:

Annals of Internal Medicine

Publication Date:

August 27, 2019

URL:

Assessment and Management of Patients at Risk for Suicide: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines.

Format:

Article

DOI (1):

10.7326/M19-0687

Keywords

MeSH

evidence-based practice

DESCRIPTION:

In May 2019, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved an update to the 2013 joint clinical practice guideline for assessing and managing patients who are at risk for suicide. This guideline provides health care providers with a framework by which to screen for, evaluate, treat, and manage the individual needs and preferences of VA and DoD patientswho may be at risk for suicide.

METHODS:

In January 2018, the VA/DoD Evidence-Based Practice Work Group convened to develop a joint VA/DoD guideline including clinical stakeholders and conforming to the National Academy of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel drafted key questions, systematically searched and evaluated the literature through April 2018, created algorithms, and advanced 22 recommendations in accordance with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.

RECOMMENDATIONS:

This synopsis, which includes 3 clinical practice algorithms, summarizes the key recommendations of the guideline related to screening and evaluation, risk management and treatment, and other management methods. Risk management and treatment recommendations address both pharmacologic and nonpharmacologic approaches for patients with suicidal ideation and behavior. Other management methods address lethal means safety (such as restricting access to firearms, poisons, and medications and installing barriers to prevent jumping from lethal heights) and population health strategies.

Free full text

View

These guidelines produced by the VA apply equally well to all adults. James W. Mold, MD, MPH

Author/s:

Sall, J., Brenner, J., Bell, A.M.M., Colston, M.J.

Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers

John Bayhi — Fri, 02 Aug 2019 17:59:06 +0000

Date Added:

August 2, 2019

Journal/Publication:

Clinical Diabetes

Publisher:

American Diabetes Association

Publication Date:

January 1, 2019

Issue:

Volume:

Pages:

11-34

URL:

Standards of Medical Care in Diabetes — 2019 Abridged for Primary Care Providers

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.2337/cd18-0105

Keywords

PMID (1):

30705493

MeSH

diabetes mellitus

diabetes mellitus, type 2

diabetes mellitus, type 1

blood glucose

Prediabetic State

Glucose Tolerance Test

Treatment Adherence and Compliance

Standard of Care

self-management

This is the 2019 version of the ADA Guidelines for managing diabetes in primary care. James W. Mold, MD, MPH

Free full text

View

The American Diabetes Association’s (ADA’s) Standards of Medical Care in Diabetes is updated and published annually in a supplement to the January issue of Diabetes Care. The ADA’s Professional Practice Committee, which includes physicians, diabetes educators, registered dietitians (RDs), and public health experts, develops the Standards. The Standards include the most current evidence-based recommendations for diagnosing and treating adults and children with all forms of diabetes. ADA’s grading system uses A, B, C, or E to show the evidence level that supports each recommendation.

A—Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered
B—Supportive evidence from well-conducted cohort studies
C—Supportive evidence from poorly controlled or uncontrolled studies
E—Expert consensus or clinical experience

This is an abridged version of the 2019 Standards containing the evidence-based recommendations most pertinent to primary care. The tables and figures have been renumbered from the original document to match this version. The complete 2019 Standards of Care document, including all supporting references, is available at professional.diabetes.org/standards.

Author/s:

American Diabetes Association

Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People

Brian Desmarais — Wed, 26 Jun 2019 21:56:55 +0000

Date Added:

June 26, 2019

Publisher:

UCSF Center of Excellence for Transgender Health

Publication Date:

June 17, 2019

URL:

Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

Keywords

MeSH

Antineoplastic Combined Chemotherapy Protocols

Cytarabine

Etoposide

Methotrexate

referral and consultation

Standard of Care

Guidelines for providing gender-affirming care for LGBTQ patients. I recommend pages 15-18 even if you have no interest in the rest of the material in the guideline. James W. Mold, MD, MPH

Free full text

View

Introduction to the guidelines The Center of Excellence for Transgender Health (CoE) at the University of California – San Francisco is proud to present these Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. Transgender people have a gender identity that differs from the sex which they were assigned at birth, and are estimated to represent 0.5% of the U.S. population.[1] Numerous needs assessments have demonstrated that transgender people encounter a range of barriers to accessing primary health care. A 2006 survey of more than 600 transgender people in California found that 30% postponed seeking medical care due to prior disrespect or discrimination, and that 10% were primary care outright.[2] The 2011 National Transgender Discrimination Survey of more than 6000 transgender people in all 50 U.S. states found several noteworthy disparities, including 28% who delayed care due to past discrimination and 19% who were denied care outright. Most alarmingly, 50% of respondents reported having to teach their providers about their own healthcare.[3] These guidelines aim to address these disparities by equipping primary care providers and health systems with the tools and knowledge to meet the health care needs of their transgender and gender nonconforming patients. These guidelines expand on the original UCSF Primary Care Protocol for Transgender Care, which since its launch in 2011 has served thousands of providers and policymakers across the U.S. and around the world; the page on hormone administration alone received more than 5000 visitors in the month of November, 2015. These Guidelines complement the existing World Professional Association for Transgender Health Standards of Care and the Endocrine Society Guidelines in that they are specifically designed for implementation in every day evidence-based primary care, including settings with limited resources.[4,5] The overall structure and list of topics for inclusion were developed in consultation with the CoE’s Medical Advisory Board (MAB), a diverse group of expert clinicians from a variety of academic and community based settings. Also contributing to the overall design and structure was a review of the range of consultation requests received by the CoE since the 2011 launch of the original Protocol. The guidelines were then written using an authorship – peer review approach. Primary authors from both within and outside the MAB were invited for individual topics, after which a peer review and modified consensus process was used to arrive at the final guidelines presented here. The diverse authorship allows the development of a broadly applicable document, rather than one that solely reflects the practice at a single academic medical center, such as UCSF. These guidelines would not be possible without the contributions of our Medical Advisory Board and other authors and reviewers, as well as the support of my CoE colleagues JoAnne Keatley, MSW and E. Michael Reyes, MD, MPH, as well as Lissa Moran who assisted immensely with literature reviews, bibliography management, version control, copy editing, formatting, and compiling peer reviewer comments. Ben Zovod also assisted with literature reviews, bibliography management, and compiling peer reviewer comments. Their dedication and hours of hard work has resulted in a final product that is relevant, broadly applicable, evidence based, and scientifically sound. I hope you find these guidelines useful and welcome any feedback or questions, which are June 17, 2016 2 Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People helpful in framing future revisions. Thank you for caring about the health of transgender and gender nonconforming people. Madeline B. Deutsch, MD, MPH Editor Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People Director of Clinical Services Center of Excellence for Transgender Health Associate Professor of Clinical Family and Community Medicine Department of Family and Community Medicine University of California, San Francisco Madeline.Deutsch@ucsf.edu

Clinically Diagnosing Pertussis-associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report

Tracy Ashby — Mon, 11 Feb 2019 06:00:00 +0000

Date Added:

February 11, 2019

Journal/Publication:

Chest

Publisher:

American College of Chest Physicians

URL:

Clinically Diagnosing Pertussis-associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.1016/j.chest.2018.09.027

Keywords

cough

evidence-based medicine

guidelines

infectious disease

diagnosis

PMID (1):

30321509

MeSH

diagnostic tests, routine

Pertussis is relatively common these days. Protection from the vaccine is relatively short-lived. Treatment decisions must usually be made clinically prior to the results of lab test results. This guideline provides information useful for the clinical diagnosis of pertussis in both children and adults.

Commercial full text (fees may apply)

View

BACKGROUND:

The decision to treat a suspected case of pertussis with antibiotics is usually based on a clinical diagnosis rather than waiting for laboratory confirmation. The current guideline focuses on making the clinical diagnosis of pertussis-associated cough in adults and children.

METHODS:

The American College of Chest Physicians (CHEST) methodologic guidelines and the Grading of Recommendations, Assessment, Development, and Evaluation framework were used. The Expert Cough Panel based their recommendations on findings from a systematicreview that was recently published on the topic; final grading was reached by consensus according to Delphi methodology. The systematic review was carried out to answer the Key Clinical Question: In patients presenting with cough, how can we most accurately diagnose from clinical features alone those who have pertussis-associated cough as opposed to other causes of cough?

RESULTS:

In adults, after pre-specified meta-analysis exclusions, pooled estimates of sensitivity and specificity were generated for only 4 clinical features: paroxysmal cough, post-tussive vomiting, inspiratory whooping, and absence of fever. Both paroxysmal cough and absence of fever had high sensitivity (93.2% [95% CI, 83.2-97.4] and 81.8% [95% CI, 72.2-88.7], respectively) and low specificity (20.6% [95% CI, 14.7-28.1] and 18.8% [95% CI, 8.1-37.9]). Inspiratory whooping and posttussive vomiting had a low sensitivity (32.5% [95% CI, 24.5-41.6] and 29.8% [95% CI, 18.0-45.2]) but high specificity (77.7% [95% CI, 73.1-81.7] and 79.5% [95% CI, 69.4-86.9]). In children, after pre-specified meta-analysis exclusions, pooled estimates of sensitivity and specificity were generated for only 1 clinical feature in children (0-18 years): posttussive vomiting. Posttussive vomiting in children was only moderately sensitive (60.0% [95% CI, 40.3-77.0]) and specific (66.0% [95% CI, 52.5-77.3]).

CONCLUSIONS:

In adults with acute (< 3 weeks) or subacute (3-8 weeks) cough, the presence of whooping or posttussive vomiting should rule in a possible diagnosis of pertussis, whereas the lack of a paroxysmal cough or the presence of fever should rule it out. In children with acute (< 4 weeks) cough, posttussive vomiting is suggestive of pertussis but is much less helpful as a clinical diagnostic test. Guideline suggestions are made based upon these findings and conclusions.

Author/s:

Moore, Abigail, Harnden, Anthony, Grant, Cameron C., Patel, Sheena, Irwin, Richard S.